- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
JP Morgan led the pack of the top 20 global financial advisers for the Healthcare industry in the latest mergers and acquisitions (M&As) league table for Q2 2018, compiled by GlobalData, a leading data and analytics company.
Orilissa Endometriosis drug uptake will be restricted
Following the recent approval of AbbVie’s Orilissa (elagolix) by the FDA, the Institute for Clinical and Economic Review (ICER) highlighted uncertainties about the oral pain relief medication’s long-term safety and clinical benefits, as well as cost-effectiveness over available alternative treatments.
There has been a negative shift in Brexit sentiment in the UK healthcare sector, finds GlobalData
There has been a negative shift in sentiment in the way that members of the UK healthcare sector perceive Brexit, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Brexit and the Healthcare Industry’ found that in July 2018, 37% of those from the UK healthcare industry believed that the UK […]
North Americans are the least informed about GDPR in Pharma
North Americans were the least likely to say that they feel informed about the requirements of the General Data Protection Regulation (GDPR) out of those surveyed in the global pharmaceuticals industry, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ states that only 54% of North […]
‘No Brexit’ is the preferred, but not the most likely outcome of Brexit for the Pharma industry
Reversal of the referendum result is indicated as the best outcome of Brexit for the healthcare industry out of those surveyed in the pharmaceuticals industry, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Brexit and the Healthcare Industry’ states that 48% of participants across the US, UK, and EU felt […]
P&G needs to mitigate impact of growing production costs to drive earnings forward despite showing positive net sales growth in Q4 results
‘‘P&G’s fourth quarter results indicate positive net sales growth of 3%. However an increase in costs of 9% in its supply chain has served to reduce net earnings compared with the same period in 2017. The company will need to reduce its supply and manufacturing overheads or consider increasing its prices to mitigate the impact of growing commodity costs experienced across the consumer goods landscape on its bottom line.
Virgin Care take advantage of creaking NHS as the company picks up £2bn worth of contracts in the last 5 years
Following the news that Virgin has been awarded up to £2bn worth of NHS contracts in the last five years,
US banking giants top GlobalData league table for Q2 deals activity
Morgan Stanley topped the deals activity league table for the second quarter of 2018, according to latest deals advisors research by GlobalData, a leading data and analytics company.
Top twenty ranking of law firms by deal activity revealed
US law firm Sullivan & Cromwell was top of the tree in terms of global deals activity in the second quarter of 2018, according to a new league table compiled by GlobalData, a leading data and analytics company.
GDPR has had a greater impact on R&D in healthcare compared to other industries
R&D departments in healthcare organisations have felt a significantly higher impact due to the General Data Protection Regulation (GDPR) than in other sectors, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ finds that, whilst most business departments have been affected similarly regardless of which sector […]
Merck and InnoCore collaboration could be a step forward for biologic drug delivery
Following today’s (Friday 3 August) announcement of Merck and InnoCore’s collaboration, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this might mean for biologic drug delivery: “One of the biggest environmental unmet needs in the pharmaceutical market is a lack of compliance. Whether this is due […]
Card infrastructure is showing its age
Following the news (Thursday 2 August) that NatWest debit cards were unusable for two hours this afternoon, Sam Murrant, Senior Payments Analyst at GlobalData, a leading data and analytics company, offers his view on the future of card-based payments: “The payments industry is increasingly moving towards an assumption that we will pay for everything electronically […]
A dramatic shift in the treatment paradigm in lung cancer is on the horizon
As part of World Lung Cancer Day 2018, Volkan Gunduz, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the changing lung cancer treatment landscape: ”The lung cancer treatment landscape is currently undergoing a notable reduction in the clinical development of chemotherapies and a significant increase in the […]
Launch of Aimovig signals the start of a boom in the European migraine market
Following the launch of Novartis’ anti-migraine drug, Aimovig, in Europe, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the potential growth of the market: “The calcitonin gene-related peptide (CGRP) monoclonal antibody class has generated significant excitement among headache specialists since posting promising efficacy results in early stage […]
Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results
Following the announcement of a significant dip in first-quarter operating profit for Takeda, Thomas Moore, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s future: “Takeda’s first-quarter operating profits took a 49% hit year-on-year, and represent the weakest first quarter profit in the last three years. Looking […]
Merck KGaA looking to become a key player in the multiple sclerosis market as the FDA accept Mavenclad for review
Following the announcement that the FDA have accepted Merck KGaA’s resubmitted application for Mavenclad, seven years after the original application, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s current progress: “Merck KGaA have placed themselves in a strong position in the multiple sclerosis market with […]
Cash is not dead yet
Following the announcement (Friday 27 July) that there will be a review for cash access after a surge in digital payments, Sam Murrant, Senior Payments Analyst at GlobalData, a leading data and analytics company, offers his view on the future of cash payments: “Cash in the UK is by no means as dead or dying […]
Nestlé volume growth in the first half of 2018 driven by on-trend new products, sales to China and positive core category performance
Nestlé’s half year results show continued positive volume growth performance for the group in H1 2018, although relatively weak pricing growth indicates a greater need for Premiumization to build value in the long-term.
Quorn’s investments in vegan foods is further evidence that veganism successfully captures consumers’ secondary dieting concerns
Following yesterday’s news (Monday 23 July) that Quorn is to invest a further £7m in R&D to create more vegan products, Will Grimwade, Associate Analyst at GlobalData, a leading data and analytics company, suggests this is indicative of a wider trend: “Quorn’s decision to continue to orientate their new products towards the vegan market is […]
Overall global risk remains flat in Q1 2018
According to the latest results from the ‘Country Risk Index’ (GCRI) compiled by GlobalData, a leading data and analytics company, the overall global risk score remained flat at 40.1 out of 100 in Q1 2018 – unchanged from Q3 2017, following a reduction from 40.4 in Q2 2017. The company’s index is a unique country […]